Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS’s ECO Synthesis platform targets the expanding siRNA/RNA ...
President and CEO Alison Moore outlined the company’s strategic focus on RNA medicines manufacturing at TD Cowen’s 46th ...
San Francisco-based biotechnology company Codexis has reported strong fourth-quarter and fiscal year 2025 financial results, with the company's focus on RNA medicine gaining significant momentum. In a ...
A team from University of Toronto Engineering is the first to synthesize long noncoding RNA (lncRNA) outside the cell—a new approach to drug discovery that has already yielded some promising ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...
Inside every cell, thousands of molecular signals collide, overlap, and compensate, obscuring the true drivers of gene expression. Scientists have now developed a way to silence that cellular noise, ...
From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...
A single enzyme that can generate all four nucleotide triphosphates, the building blocks of ribonucleic acid (RNA), was identified by researchers at the Institute of Science Tokyo. By using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results